Session » Abstracts: Rheumatoid Arthritis – Treatment I: Preventative and Novel Treatments (1674–1679)

Date: Monday, October 27, 2025

Time: 1:00PM-2:30PM

Meeting: ACR Convergence 2025

1:00PM-1:15PM: Abstract Number: 1674

A Phase 2, Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Individuals At-Risk for Future Rheumatoid Arthritis

1:15PM-1:30PM: Abstract Number: 1675

Neuroimmune modulation in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors (TNFi)

1:30PM-1:45PM: Abstract Number: 1676

Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients With Rheumatoid Arthritis: 7-Year Data From the SELECT-COMPARE Study

1:45PM-2:00PM: Abstract Number: 1677

First line anti-TNF therapy in early rheumatoid arthritis is associated with a lower frequency of difficult-to-treat disease at five years and better long-term outcomes compared with usual care

2:00PM-2:15PM: Abstract Number: 1678

Abatacept in individuals at risk of developing rheumatoid arthritis: results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept Long Term Outcomes (ALTO) Study

2:15PM-2:30PM: Abstract Number: 1679

Does First-Line b- or tsDMARDs Choice Influence Progression to Difficult-to-Treat Rhumatoid arthritis? Insights from our longitudinal RA UCLouvain Brussels cohort

« View all sessions from this meeting